Lloyd Clark, W.
Liu, Mimi
Kitchens, John
Wang, Pin-wen
Haskova, Zdenka
Funding for this research was provided by:
Genentech
Article History
Received: 25 July 2018
Accepted: 14 December 2018
First Online: 8 January 2019
Ethics approval and consent to participate
: This study includes research conducted on human subjects. The study protocol was prospectively approved by the institutional review board at each study site, and the study was conducted according to the International Conference on Harmonisation E6 Guideline for Good Clinical Practice and any national requirements. Patients provided written, informed consent for the trial and for future medical research and analyses based on results of the trial. The existing data from this clinical trial were assessed retrospectively by exploratory analyses. The study sponsor, Genentech, Inc., granted permission to use the data. No patient identifiable information was connected with the datasets used for these retrospective analyses.
: Not applicable.
: The authors have made the following disclosures: WLC has received grant support and served on the speakers’ bureau and as a consultant for Genentech, Inc./Roche (South San Francisco, CA) and Regeneron Pharmaceuticals (Tarrytown, NY); has received travel support and honoraria from Bayer (Leverkusen, Germany); has received grant support and served as a consultant for Santen (Osaka, Japan); and has received grant support from Allergan (Dublin, Ireland). ML has no financial conflicts of interest to disclose. JK has served as a consultant for Alcon (Forth Worth, TX), Allergan (Dublin, Ireland), Genentech, Inc. (South San Francisco, CA), Regeneron (Tarrytown, NY), and ThromboGenics (Leuven, Belgium); and has served as a consultant for and holds stock in Synergetics (O’Fallon, MO). P-wW and ZH are employees of Genentech, Inc. (South San Francisco, CA).
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.